Article
PKC-alpha promotes phosphorylation of KRAS suppressing its oncogenic properties
2022-05-25
Abstract excerpt
Oncogenic KRAS-driven cancers have long been considered as “undruggable” due to limited therapeutic options. While the recent success of KRAS-G12C inhibitors argues against the “undruggability” of KRAS, this treatment only benefits a small proportion of patients with KRAS mutant cancers, leaving an urgent need for modalities to target other KRAS mutants. KRAS-calmodulin (CaM) signaling axis reportedly regulates th...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a3f1a269-8e58-5cb7-8caf-1bb6fe3dd7e3
- DOI
- 10.1101/2022.05.24.493257
